Cilostazol Enhances the Number and Functions of Circulating Endothelial Progenitor Cells and Endothelial Function Mediated Through Modification of Vasculogenesis and Angiogenesis Factors in Patients With Stable Coronary Artery Disease
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Cilostazol (Primary)
- Indications Coronary artery disease; Myocardial infarction
- Focus Therapeutic Use
Most Recent Events
- 07 Dec 2014 Modified secondary endpoints, inclusion - exclusion criteria and changed planned patient number from 60 to 300, as reported by ClinicalTrials.gov.
- 29 Jul 2014 New trial record